宜明昂科-b(01541)午后涨超9%,截至发稿,涨8.68%,报14.28港元,成交额6045.06万港元。国元国际指出,宜明昂科是CD47融合蛋白全球创新引领者,管线丰富,在肿瘤及自免领域应用前景广阔。IMM0306治疗自身免疫性疾病临床试验目前进行Ib期爬坡试验,目前SLE的试验有10例患者入组,试验顺利推进,应答情况较好,有望于6月出数据。目前全球治疗自身免疫性疾病的生物创新药物紧缺,有望...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.